The purpose of this research study is to collect information on the safety of the TactiCath SE ablation catheter when it is used to treat atrial fibrillation.This study will collect information about the success of the procedure and report on the number and type of follow-up problems that may occur during or after the ablation procedure (sometimes called adverse events). Data collected for this study will be submitted for review and approval by the FDA.
The purpose of this study is to learn if taking a drug called apixaban, given orally, before and after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in VT (ventricular tachycardia) patients. Apixaban is a blood thinning drug, also called an anticoagulant. Apixaban is compared to Aspirin. Aspirin is mainly used to treat fever, pain and inflammatory conditions such as arthritis.
VIVO is a non-FDA approved software product that uses a laptop computer and a handheld Kinect 3D camera. VIVO combines patient-specific images from either a CT scan or MRI of the torso and cardiac structures with a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart. The purpose of the study is to give the FDA more information about the accuracy and safety of VIVO. Information will be collected about the participant and the ablation procedure he/she is scheduled to have.The VIVO algorithm will be used to assess the accuracy of VIVO to create a patient- specific model, thus improving the accuracy of locating the irregular heartbeats during an ablation procedure.